The a2 Milk Company faces significant supply chain disruptions in China, dampening its infant formula sales and forcing a downgrade of its FY26 financial outlook despite robust demand.
- Strong infant formula demand in China offset by supply shortages
- Freight delays linked to Middle East conflict exacerbate product availability
- Synlait production backlog and new quality testing extend delays
- FY26 revenue growth forecast trimmed to low-mid double digits
- EBITDA margin expected to fall to around 14%-14.5%
Robust Demand Meets Supply Chain Headwinds
The a2 Milk Company (ASX:A2M) continues to see strong appetite for its infant milk formula (IMF) products across China, with third-quarter 2026 sales reflecting sustained or improved year-to-date momentum. The China label a2 至初™ formula and English label products like a2 Platinum™ and a2 Genesis™ have enjoyed solid growth, bolstered by marketing efforts such as the My Little Pony campaign and gains in cross-border e-commerce channels.
However, this demand surge collides with a series of supply chain disruptions that are now materially constraining product availability in key Chinese markets. The company highlights a complex mix of factors including freight bottlenecks, production backlogs, and regulatory hurdles as the root causes.
Freight and Production Challenges Amplified by Geopolitical Tensions
International air freight capacity, critical for timely product shipments to China, is being indirectly squeezed by the ongoing Middle East conflict, which has caused variability in sea and air freight allocations. This external shock compounds existing production issues at Synlait, a2 Milk’s manufacturing partner, which has struggled with operational challenges and reduced capacity following asset sales. Although Synlait’s output has recently returned to target levels, a significant backlog of unfulfilled orders remains.
Adding to delays, new quality assurance protocols involving enhanced cereulide testing and stricter customs clearance procedures have extended product release times. These factors collectively have led to temporary shortages of China label IMF products at distributors and retailers, particularly expected to worsen in April and May 2026.
Supply Chain Transformation and Recovery Plans
On a more positive note, a2 Milk’s supply chain transformation program at its a2 Pōkeno facility remains on track. Capital upgrades, recruitment, product trials, and regulatory registration amendments are progressing well, with a production ramp-up anticipated in the first half of 2027. The company also expects to resolve near-term availability issues for a2 Genesis™ products in cross-border e-commerce channels once planned maintenance and capital works on the canning line are completed.
This ongoing investment in supply chain resilience follows the company’s earlier strategic moves, including the acquisition of a2 Pōkeno, which helped advance its supply chain control and supported its strong half-year results earlier in 2026. Those results had prompted a positive upgrade to FY26 guidance, reflecting a period of growth and confidence in the business trajectory.
Downgraded FY26 Outlook Amid Uncertainty
Despite these efforts, the cumulative impact of supply disruptions and external uncertainties now forces a2 Milk to revise its FY26 guidance downward. The company now expects low to mid double-digit revenue growth; down from its previous mid double-digit forecast; with EBITDA margins trimmed to approximately 14.0% to 14.5% from 15.5% to 16.0%. Net profit after tax (NPAT) is anticipated to be flat or slightly down on FY25’s $203 million, reversing earlier expectations of growth.
Cash conversion is also projected to decline sharply to about 50%, reflecting delayed cash receipts due to slower sales in the final quarter. Capital expenditure is planned at $60 to $80 million as the company continues to invest in long-term supply chain upgrades. These revisions underline the challenges of navigating supply chain complexities amid geopolitical tensions and evolving regulatory environments.
Key risks remain, including further freight and customs delays, competitive pressures in China’s IMF market, macroeconomic headwinds, and ongoing impacts from the Middle East conflict. How the company manages these variables will be critical to its performance in the near term.
Bottom Line?
a2 Milk’s FY26 performance now hinges on resolving supply chain bottlenecks and navigating external geopolitical risks as it balances short-term disruptions with long-term growth investments.
Questions in the middle?
- How quickly can a2 Milk clear the backlog of Synlait orders and restore full production capacity?
- What impact will ongoing Middle East freight disruptions have on supply chain stability beyond mid-2026?
- Can the company’s supply chain transformation at a2 Pōkeno sufficiently mitigate future production and quality assurance delays?